Quarterly ResultMay 14, 2026, 07:37 AM
REGENXBIO Q1 Net Loss $(90.1)M; Revenue Down 92.8%; Going Concern Doubt
AI Summary
REGENXBIO Inc. reported a significant net loss of $(90.05) million for the first quarter of 2026, a sharp decline from a net income of $6.08 million in the same period last year. Total revenues plummeted by 92.8% to $6.39 million, primarily due to a substantial drop in license and royalty revenue. The company also disclosed that its cash, cash equivalents, and marketable securities of $150.5 million are only sufficient to fund operations into early 2027, raising substantial doubt about its ability to continue as a going concern.
Key Highlights
- REGENXBIO reported a net loss of $(90.05) million for Q1 2026, down from $6.08 million net income in Q1 2025.
- Total revenues decreased by 92.8% to $6.39 million in Q1 2026 from $89.01 million in Q1 2025.
- License and royalty revenue fell to $5.09 million in Q1 2026 from $87.05 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $150.5 million as of March 31, 2026.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- Net cash used in operating activities was $(76.19) million in Q1 2026, compared to $33.63 million provided in Q1 2025.
- Research and development expenses increased to $57.34 million in Q1 2026 from $53.09 million in Q1 2025.